Background: Evidence has demonstrated that adding intermittent inhaled corticosteroids (ICS) to treatment with short-acting b2-agonists (SABAs) in children 5 years of age and younger who experience intermittent viral-induced wheezing (VIW) reduces the risk of severe exacerbations. However, there is concern about whether the extra benefit offered by this drug outweighs the additional cost. This study aimed to evaluate the cost-effectiveness of intermittent ICS in children 5 years of age and younger who experience intermittent VIW.

中文翻译：

---

病毒触发喘息学龄前儿童间歇性吸入皮质类固醇的成本效用

背景：有证据表明，对于 5 岁及以下经历间歇性病毒性喘息 (VIW) 的儿童，在短效 b2 受体激动剂 (SABA) 的治疗中加入间歇性吸入皮质类固醇 (ICS) 可降低严重恶化的风险。然而，人们担心这种药物提供的额外好处是否超过了额外的成本。本研究旨在评估间歇性 ICS 对 5 岁及以下经历间歇性 VIW 的儿童的成本效益。